AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8685201 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 30 mg/day
Number of subjects: 315
Study 8685201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 37.5 mg
Number of subjects: 315
Study 8685201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment by patient and investigator
Number of subjects: 315
Study 1524161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 0
Study 1524161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg daily
Number of subjects: 0
Study 6741676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 50
Study 6741676 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 50
Study 30607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ial System Duo
Number of subjects: 59
Study 30607570 — intervention group
Group type: EXPERIMENTAL
Intervention: Belotero Basic/Balance
Number of subjects: 59
Study 30552263 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, progressive treadmill walking exercise training three times per week for a 3-month period.
Number of subjects: 40
Study 30552263 — intervention group
Group type: COMPARATOR
Intervention: Supervised, progressive low-intensity resistive exercise three times per week for a 3-month period.
Number of subjects: 40
Study 27189616 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly supervised exercise intervention (endurance and resistance exercise)
Number of subjects: 153
Study 27189616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 24686107 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) administered in ambulances
Number of subjects: 2079
Study 22831888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant alone
Number of subjects: 120
Study 22831888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant with scopolamine
Number of subjects: 120
Study 20048611 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Steri-Strip S Surgical Skin Closure
Number of subjects: 51
Study 17279852 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0
Study 17279852 — intervention group
Group type: COMPARATOR
Intervention: Initial acts of self-control
Number of subjects: 0
Study 16216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish applied at 3-month intervals (CHX group)
Number of subjects: 200
Study 16216096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, group C)
Number of subjects: 200
Study 16216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish (CHX group)
Number of subjects: 200
Study 16216096 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 200
Study 12011122 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73)
Number of subjects: 143
Study 12011122 — intervention group
Group type: COMPARATOR
Intervention: rituximab 375 mg/m2 IV weekly for four doses (n = 70)
Number of subjects: 143
Study 9892509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial prostaglandin E1 (10 microg i.a. over 30 min)
Number of subjects: 30
Study 9892509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (15 microg i.v. over 30 min)
Number of subjects: 30
Study 7619644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills training program focused on sexual assertiveness skills and reduction of risk-related behaviors
Number of subjects: 0
Study 7619644 — intervention group
Group type: COMPARATOR
Intervention: Education-only program
Number of subjects: 0
Study 7619644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills training program
Number of subjects: 0
Study 2551907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polymyxin B during the first week after burn injury
Number of subjects: 2
Study 2551907 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative polymyxin B given in conjunction with an excisional procedure of the burn wound
Number of subjects: 2
Study 61952 — intervention group
Group type: EXPERIMENTAL
Intervention: FZ. 560 (combination of fentonium bromide 10 mg, dehydrocholic acid 25 mg, pancreatin 50 mg, lactulose 200 mg)
Number of subjects: 37
Study 61952 — intervention group
Group type: COMPARATOR
Intervention: Fentonium bromide 10 mg (control group)
Number of subjects: 37
Study 61952 — intervention group
Group type: COMPARATOR
Intervention: Other components (control group)
Number of subjects: 37
Study 31018678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in stepped-wedge trials with more than two levels of clustering
Number of subjects: 0
Study 31018678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and non-standard designs for stepped-wedge trials
Number of subjects: 0
Study 29084409 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin alfa)
Number of subjects: 49
Study 29084409 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (reference medicine)
Number of subjects: 49
Study 26416999 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T; 90 mg/m2 epirubicin, 600 mg/m2 cyclophosphamide, 100 mg/m2 docetaxel)
Number of subjects: 1384
Study 26416999 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel followed by capecitabine (ET-X; 90 mg/m2 epirubicin, 75 mg/m2 docetaxel, 1250 mg/m2 capecitabine)
Number of subjects: 1384
Study 26416999 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T)
Number of subjects: 1384
Study 26416999 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel followed by capecitabine (ET-X)
Number of subjects: 1384
Study 22193920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity LTPA (>2,000 kcal/week)
Number of subjects: 19003
Study 22193920 — intervention group
Group type: EXPERIMENTAL
Intervention: Total LTPA (>3,000 kcal/week)
Number of subjects: 19003
Study 22193920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity activities (>50% of total LTPA)
Number of subjects: 19003
Study 20393362 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + acamprosate
Number of subjects: 786
Study 20393362 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + naltrexone
Number of subjects: 786
Study 20393362 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + acamprosate + naltrexone
Number of subjects: 786
Study 20393362 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + acamprosate + combined behavioral intervention
Number of subjects: 786
Study 20393362 — intervention group
Group type: COMPARATOR
Intervention: Medical management + placebo (MM + placebo)
Number of subjects: 786
Study 18521462 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 2.5%
Number of subjects: 102
Study 18521462 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 1.5% combined with 50% nitrous oxide and oxygen
Number of subjects: 102
Study 15986587 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function testing using the 'Sniffin' Sticks' technique
Number of subjects: 45
Study 15986587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to identify odors
Number of subjects: 45
Study 15986587 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric function tests
Number of subjects: 45
Study 15986587 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of bilirubin and zinc
Number of subjects: 45
Study 15986587 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiology of CL (e.g., alcoholism)
Number of subjects: 45
Study 12701670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 12701670 — intervention group
Group type: COMPARATOR
Intervention: Medication and placebo (control group)
Number of subjects: 0
Study 12701670 — intervention group
Group type: COMPARATOR
Intervention: Analytical psychotherapy (control group)
Number of subjects: 0
Study 10499654 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted cardioplegia
Number of subjects: 40
Study 10499654 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia without leucocyte depletion
Number of subjects: 40
Study 7569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust Bayesian methods
Number of subjects: 0
Study 7569495 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 1952204 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 40
Study 1952204 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl infusion
Number of subjects: 40
Study 7019930 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tiaprofenic acid given 3-times daily for 7 days
Number of subjects: 50
Study 7019930 — intervention group
Group type: COMPARATOR
Intervention: 600 mg aspirin given 3-times daily for 7 days
Number of subjects: 50
Study 29040445 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg b.i.d. ticagrelor
Number of subjects: 50
Study 29040445 — intervention group
Group type: COMPARATOR
Intervention: 90 mg b.i.d. ticagrelor
Number of subjects: 50
Study 26395889 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 or 200 mg)
Number of subjects: 0
Study 25516879 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (P90 System Adhesive Self‐Etch Primer and Bond and Filtek P90 Low Shrink Posterior Restorative)
Number of subjects: 100
Study 25516879 — intervention group
Group type: COMPARATOR
Intervention: Dimethacrylate-based composite (Adper SE Plus and Filtek P60 Posterior Restorative)
Number of subjects: 100
Study 22369102 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 927
Study 22369102 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized youth (control)
Number of subjects: 927
Study 20113303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 88
Study 20113303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychoeducation (PE)
Number of subjects: 88
Study 18971408 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-providers (CPs)
Number of subjects: 93
Study 16159631 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant grass pollen allergens
Number of subjects: 0
Study 14741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume control (VC)
Number of subjects: 114
Study 14741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure control (PC)
Number of subjects: 114
Study 10551575 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine (diluted with NaCl 0.9%)
Number of subjects: 90
Study 10551575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (diluted with NaCl 10.9% and glucose 30%)
Number of subjects: 90
Study 10551575 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study 8673548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment (31 Chinese herbs), 28 tablets each day
Number of subjects: 30
Study 8673548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose placebo), 28 tablets each day
Number of subjects: 30
Study 1890532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% AmF gel
Number of subjects: 0
Study 1890532 — intervention group
Group type: COMPARATOR
Intervention: 0.125% AmF toothpaste
Number of subjects: 0
Study 1890532 — intervention group
Group type: COMPARATOR
Intervention: 0.4% F gel
Number of subjects: 0
Study 1890532 — intervention group
Group type: COMPARATOR
Intervention: 0% F gel
Number of subjects: 0
Study 1890532 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups during 6-month discontinuation
Number of subjects: 0
Study 1890532 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF-treated groups
Number of subjects: 0
Study 6311009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdinocillin
Number of subjects: 299
Study 6311009 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin or other comparative agents
Number of subjects: 299
Study 6311009 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 299
Study 30536970 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 85
Study 30536970 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 85
Study 30536970 — intervention group
Group type: COMPARATOR
Intervention: Cold argon plasma
Number of subjects: 85
Study 29342199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose metformin (375 mg followed by 250 mg)
Number of subjects: 20
Study 29342199 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose metformin (1000 mg followed by 1000 mg)
Number of subjects: 20
Study 29342199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of metformin
Number of subjects: 20
Study 26774115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (500 μg) and folic acid (400 μg)
Number of subjects: 2919
Study 24815501 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 24815501 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 0
Study 24815501 — intervention group
Group type: EXPERIMENTAL
Intervention: Interhospital transfers
Number of subjects: 0
Study 24815501 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in the same center
Number of subjects: 0
Study 24815501 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial progression
Number of subjects: 0
Study 21971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural Tramadol (Group TPN)
Number of subjects: 120
Study 21971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Tramadol (Group TIM)
Number of subjects: 120
Study 21971437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 120
Study 21971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group TPN vs Group TIM
Number of subjects: 120
Study 20646181 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (50mg bid)
Number of subjects: 892
Study 20646181 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (50-100mg bid)
Number of subjects: 892
Study 20646181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892
Study 20646181 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20mg qd)
Number of subjects: 892
Study 20646181 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20-40mg qd)
Number of subjects: 892
Study 17565489 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone
Number of subjects: 66
Study 17565489 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 66
Study 17565489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16485509 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (not specified in detail)
Number of subjects: 11
Study 16485509 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications (antiparkinsonian drugs)
Number of subjects: 11
Study 16485509 — intervention group
Group type: COMPARATOR
Intervention: Normal participants (control group)
Number of subjects: 11
Study 12427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at closer distance (2 m)
Number of subjects: 4
Study 12427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at 10 ft
Number of subjects: 4
Study 12427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at 3.2 m
Number of subjects: 4
Study 12427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at closer distance (2 m) censored
Number of subjects: 4
Study 10489797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 12885
Study 10489797 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-cannabis users)
Number of subjects: 12885
Study 7492463 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 2291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 46
Study 2291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 46
Study 2291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 46
Study 2291866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7389323 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical idoxuridine 0.5% and 5% in petrolatum
Number of subjects: 60
Study 7389323 — intervention group
Group type: COMPARATOR
Intervention: Topical idoxuridine 5‐40% in dimethylsulfoxide (previous treatment)
Number of subjects: 60
Study 30334154 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary simultaneous two‐arterial occlusions (TESTO)
Number of subjects: 62
Study 30334154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 28193399 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource centre intervention
Number of subjects: 12614
Study 25899550 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative pretest probability (qPTP) for ACS and PE with advice
Number of subjects: 0
Study 25899550 — intervention group
Group type: COMPARATOR
Intervention: Sham (no qPTP and no advice)
Number of subjects: 0
Study 24954134 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% green tea mouthwash
Number of subjects: 97
Study 24954134 — intervention group
Group type: COMPARATOR
Intervention: 0.12% CHX mouth rinse
Number of subjects: 97
Study 21917635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled casein protein (PRO)
Number of subjects: 16
Study 21917635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 19116389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of ascorbic acid daily)
Number of subjects: 7627
Study 19116389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU of alpha-tocopherol every other day)
Number of subjects: 7627
Study 19116389 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg every other day)
Number of subjects: 7627
Study 19116389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7627
Study 17324218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICMs) with 0.6 microg/ml epinephrine
Number of subjects: 140
Study 17324218 — intervention group
Group type: COMPARATOR
Intervention: Intracameral mydriatics (ICMs) without epinephrine
Number of subjects: 140
Study 17324218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mydriatics (TMs) with 0.6 microg/ml epinephrine
Number of subjects: 140
Study 17324218 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics (TMs) without epinephrine
Number of subjects: 140
Study 14717965 — intervention group
Group type: EXPERIMENTAL
Intervention: SanOrg34006 2.5 mg
Number of subjects: 659
Study 14717965 — intervention group
Group type: EXPERIMENTAL
Intervention: SanOrg34006 (5.0, 7.5, 10 mg)
Number of subjects: 659
Study 14717965 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR, 2.0-3.0)
Number of subjects: 659
Study 14717965 — intervention group
Group type: EXPERIMENTAL
Intervention: SanOrg34006 (all doses)
Number of subjects: 659
Study 11749654 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise training programme
Number of subjects: 21
Study 11749654 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle control group
Number of subjects: 21
Study 9675647 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxycillin 1000 mg b.i.d. for one week
Number of subjects: 108
Study 9675647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg b.i.d. for one week
Number of subjects: 108
Study 9675647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment Delta Over Baseline at 30' value
Number of subjects: 108
Study 9675647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-treatment Delta Over Baseline at 30' values
Number of subjects: 108
Study 7516297 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 10
Study 7516297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study 2913551 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21
Study 2913551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2913551 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-term follow-up)
Number of subjects: 21
Study 1101619 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1 %
Number of subjects: 0
Study 1101619 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5 %
Number of subjects: 0
Study 31790704 — intervention group
Group type: COMPARATOR
Intervention: Computational genomic analysis of purine-pyrimidine sequences in selected genomes
Number of subjects: 3
Study 31790704 — intervention group
Group type: COMPARATOR
Intervention: Computational genomic analysis of hydrogen-bond-based HIDERs
Number of subjects: 3
Study 31053537 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-onset Acinetobacter species pneumonia (AP)
Number of subjects: 13
Study 28453340 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Number of subjects: 240
Study 28453340 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep
Number of subjects: 240
Study 28453340 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine
Number of subjects: 240
Study 25388940 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 monotherapy at 1 mg/kg IV weekly
Number of subjects: 63
Study 25388940 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 monotherapy at 2 mg/kg IV weekly
Number of subjects: 63
Study 25388940 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 + irinotecan IV semiweekly
Number of subjects: 63
Study 25388940 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63